Stoke Therapeutics has announced new data from two open-label Phase 1/2a studies and two open-label extension studies of its lead antisense therapy, STK-001, in children aged 2-18 years with Dravet syndrome. Dravet is a rare genetic epilepsy syndrome caused by haploinsufficiency.
The latest results showed substantial and durable reductions in convulsive seizure frequency (up to an 85% reduction 3 months after the last of 2 or 3 doses of 70mg) as well as improvements in multiple measures of cognition and behaviour. Two patients were seizure free at 3 and 6 months.
The improvements were seen in a highly refractory group of patients who were already taking the best available anti-seizure medicines. 85% of patients were routinely being treated with 3 anti-seizure medications.
STK-001 was generally well-tolerated. In the Phase 1/2a studies, 30% (24/81) of patients experienced a treatment-emergent adverse event that was related to the study drug. The most common were CSF protein elevations and procedural vomiting.
The Company plans to meet with regulatory agencies to discuss a registrational study that includes initial doses of 70mg followed by continued dosing at 45mg.
Stoke Therapeutics’ (STOK:NASDAQ) stock price quickly doubled on the news, finished the day 58% up as the Company announced a US$75m public offering.
https://finance.yahoo.com/news/stoke-therapeutics-announces-landmark-data-200100436.html
https://www.neurologylive.com/view/...cts-in-early-phase-studies-of-dravet-syndrome
https://www.fiercebiotech.com/biote...-epilepsy-drug-reduces-convulsive-seizures-43
- Forums
- ASX - By Stock
- PYC
- PYC - General Discussion
PYC - General Discussion, page-179
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $489.9M |
Open | High | Low | Value | Volume |
10.0¢ | 10.5¢ | 9.9¢ | $155.7K | 1.524M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 280271 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.100 |
2 | 21515 | 0.099 |
3 | 110354 | 0.098 |
1 | 50000 | 0.097 |
5 | 97736 | 0.095 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 280271 | 3 |
0.110 | 1138249 | 5 |
0.115 | 1007423 | 6 |
0.120 | 1839122 | 8 |
0.125 | 820000 | 3 |
Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
Last
10.0¢ |
  |
Change
0.005 ( 1.01 %) |
|||
Open | High | Low | Volume | ||
10.0¢ | 10.5¢ | 9.9¢ | 545587 | ||
Last updated 15.59pm 15/05/2024 ? |
Featured News
PYC (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O’Donovan, Executive Director
Gerard O’Donovan
Executive Director
SPONSORED BY The Market Online